Αρχική World News The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to Progress

The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to Progress

June 12, 2019, by Douglas Lowy, M.D.

A toddler and his father at the pediatrician's office.

The Childhood Cancer Data Initiative aims to establish more efficient ways to share and use childhood cancer data.

Credit: iStock

NCI has been busy laying the groundwork for a plan to develop an innovative childhood cancer initiative with an aggressive focus on data sharing. The goal of the initiative is to speed progress for children and adolescents and young adults (AYAs) with cancer and their families. It would be initiated with a proposed increase to NCI’s budget of $50 million beginning in fiscal year 2020 and continuing, as proposed by the White House, for a total of 10 years.

In recent years, we’ve seen great progress in treating children with cancer. In the 1970s, just over 50% of children diagnosed with cancer could expect to survive 5 years or longer. But advances in treatment have raised that figure to higher than 80% today.

However, the higher survival rates have not been seen across all pediatric cancers. Progress against some types has been limited. In addition, we still have very little insight as to why some children do very well on treatment and then later suffer a relapse.

For those children who do survive, the long-term and delayed effects from cancer and its treatment can severely diminish their quality of life. And, despite improvements in treatment, the specific causes of most pediatric cancers remain largely unknown.

Even one child dying from cancer is one child too many. Clearly, there is much more we must do to address the challenges that have hindered more rapid progress.

At NCI, we strongly believe that harnessing the power of data can be a driver of that progress, which is why the institute plans to use these proposed funds to create the Childhood Cancer Data Initiative (CCDI).

The aim of the CCDI is to establish more efficient ways to share and use childhood cancer data to help identify novel therapeutic targets and approaches, underpin new drug development, and enable new research pursuits to better understand the biology of childhood cancers.

Stay Up to Date on the CCDI

Visit the CCDI webpage to learn more about this initiative, details on upcoming events, and how to submit a poster abstract for the July 29–31 symposium.

Given that childhood and AYA cancers are relatively uncommon, accounting for approximately 1% of cancers diagnosed annually in the United States, we have a limited amount of clinical and genomic data available to study. Moreover, we currently lack efficient ways to collect, share, and integrate data from individual centers that care for children and AYAs with cancer. This greatly limits the potential for researchers to collaborate and produce complex analyses, hindering our understanding of the pathogenesis of pediatric cancer and the development of more effective and safer treatments.

Learning from Every Young Person with Cancer

The CCDI will help to maximize the utility of data collected from as many childhood and AYA cancer patients as possible, from institutions around the country and around the world. Through improved data federation, the CCDI will connect these data with an infrastructure to facilitate sharing. In doing so, we can make it easier for researchers and oncology teams to learn from the experience of every young person with cancer and make better-informed decisions for their pediatric and AYA patients.

The CCDI will be the first of its kind in terms of the quality, size, and scope of data accessibility, making it an immensely valuable asset for young patients with cancer, their families, clinicians, and researchers. The initiative has the potential to chart a path that could change the course of how cancer in young people is prevented, diagnosed, and treated.

The goals of the initiative are also aligned with efforts underway at NCI to implement the research provisions of the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act of 2018. These provisions encourage NCI to continue to support and conduct childhood and AYA survivorship research, and to enhance collection of samples for childhood and AYA cancer research. NCI anticipates that the CCDI will complement this work: data from specimens collected through STAR Act efforts will contribute to the CCDI, and CCDI data resources will also enable future survivorship research.

Shaping the Direction of the CCDI

Since the announcement of the proposed new funding for childhood cancer research in February, we have been working with Secretary of Health and Human Services Alex Azar and the White House to help inform the public about the new initiative.

To shape the scientific direction of the CCDI, NCI is hosting a planning symposium July 29–31 in Washington, DC. The symposium will gather leaders and stakeholders from academic, government, industry, and advocacy communities to discuss scientific and clinical research data needs, opportunities for developing a connected data infrastructure, ways to provide meaningful datasets for clinical care and associated research progress, and policies around collecting and sharing data. We encourage members of the public to watch the symposium by videocast.

Douglas Lowy

NCI Acting Director Douglas R. Lowy, M.D.

Credit: National Cancer Institute

A poster session at the symposium will provide presenters the opportunity to share their ideas for shaping the initiative. I invite you to submit an abstract by June 15. Consideration will be given for abstracts submitted up until June 30 if space is still available.

To encourage as many people as possible to engage in the initiative and share their thoughts, we will be launching an online public idea repository at the end of June. This is an opportunity for anyone who is interested—patients, parents, advocates, researchers, data scientists, engineers, businesses, philanthropists—to submit their ideas for how to accelerate progress against pediatric cancer. NCI will present a report on the public’s submissions at the CCDI symposium so that they may be part of the scientific dialogue. Submissions received after mid-July will be considered at a later date.

An Opportunity and a Responsibility

The CCDI complements NCI’s ongoing efforts to support a broad range of biomedical research that addresses childhood and AYA cancers, with the goal of adding to our long history of contributing to important advances, from the first uses of chemotherapy to cure children with acute lymphoblastic leukemia to the first immune-based therapies, such as dinutuximab (Unituxin) for neuroblastoma, for childhood cancers.

I am truly excited about this bold data initiative and am confident it will provide a blueprint for establishing similar data resources for adult cancers, as well as diseases beyond cancer. Importantly, maximizing the use of available data will have a profound impact on our ability to hasten progress against childhood and AYA cancers by providing important insights into prevention and opening up new opportunities for earlier diagnosis and safer, more effective treatments. We have an opportunity, and a responsibility, to use this moment to learn from every child with cancer.

I encourage you to sign up to receive email updates on the progress of CCDI.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is Feasible

Targeted therapy recommendations can be made based on the molecular profiles of tumour samples from patients with metastatic malignant mesothelioma (MM) according to findings...

News digest – targeted radiation beam, precision medicine and our early detection roadmap

<img width="620" height="348" src="https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1.jpg" class="attachment-hero size-hero" alt srcset="https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1.jpg 620w, https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1-300x168.jpg 300w, https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1-220x123.jpg 220w, https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1-150x84.jpg 150w" sizes="(max-width: 620px) 100vw, 620px" data-attachment-id="18059" data-permalink="https://scienceblog.cancerresearchuk.org/2020/10/17/news-digest-targeted-radiation-beam-precision-medicine-and-our-early-detection-roadmap/radiation_hero-3/" data-orig-file="https://scienceblog.cancerresearchuk.org/wp-content/uploads/2020/10/Radiation_hero-1.jpg" data-orig-size="620,348" data-comments-opened="1"...

A Pet Pug Helped Two Sisters Realize They Both Had Breast Cancer

Sisters Amanda Tasca and Amy Niosi are grateful for one very perceptive pug. Amanda’s dog Daisy, a gift from her husband Steve and one...

Woman with Breast Cancer May Have Saved Her Twin’s Life by Revealing Her Lumpectomy Scar

When Meagan McCallum was diagnosed with breast cancer, she had no idea that her experience might actually save her sister’s life. Meagan underwent a...

Lo que debe saber sobre el cáncer de pulmón

La Dra. Jyoti D. Patel es profesora de Medicina y directora de Oncología Torácica de la Universidad de Chicago y es editora asociada para...

Alternatives for Outdoor Foods

Autumn has arrived, but that doesn’t mean outdoor dining has to end! You might be wondering what foods you could prepare that are healthy...